Elsevier

Burns

Volume 37, Issue 7, November 2011, Pages 1154-1160
Burns

Safety and potential anticoagulant effects of nebulised heparin in burns patients with inhalational injury at Singapore General Hospital Burns Centre

https://doi.org/10.1016/j.burns.2011.07.006Get rights and content

Abstract

Background

Nebulised heparin, N-acetylcysteine (NAC) and salbutamol were shown to decrease reintubation rates, incidence of atelectasis and mortality in paediatric patients and reduce lung injury scores in adult burns patients with inhalational lung injury (ILI). Nebulised heparin, NAC and salbutamol treatment protocol was introduced in Singapore General Hospital (SGH) Burns Centre in 2006. However, safety data on the use of nebulised heparin and NAC for burns patients with ILI is not well established. In this study, we investigated the safety and potential anticoagulant effects of nebulised heparin in burns patients with ILI.

Methods

A retrospective study with historical control was conducted. The treatment group consisted of 52 mechanically ventilated adult patients, with a diagnosis of ILI as confirmed by bronchoscopy, admitted to burn intensive care unit (BICU) from the year 2006 to 2009. The group was treated with nebulised heparin, NAC and salbutamol. The control group consists of 11 mechanically ventilated BICU ILI patients treated from year 2001 to 2005 before protocol initiation. Blood coagulation indices (prothrombin time (PT), activated partial thromboplastin time (APTT) and platelet count) were monitored and bleeding incidences were assessed.

Findings

Blood coagulation indices did not suggest an increase risk of bleeding with nebulised heparin. The APTT, PT and platelet count followed a similar trend for both groups over 7 days. No clinically significant increase in bleeding risk was found to be associated with nebulised heparin.

Conclusion

Nebulised heparin was not found to potentiate the risk of bleeding in burns patients with ILI.

Introduction

Inhalation lung injury (ILI) is a leading cause of death in burns patients. In a recent multivariate analysis done at our burn centre from 2003 to 2005, ILI was found to significantly increase mortality rate from 4.5% to 50.0% [1]. The presence of ILI in burns patients is found to be associated with an increased incidence of pulmonary complications. A study by Hollingsed et al. showed that patients with ILI had a 73% incidence of respiratory failure (hypoxemia, prolonged ventilator support or multiple pulmonary infections) and a 20% incidence of acute respiratory distress syndrome (ARDS) [2]. These respiratory complications often exacerbate the clinical outcome and prognosis of burns patients [3], [4]. As such, effective respiratory management forms the corner stone in improving patients’ outcomes [5].

Heparin is an endogenous glycosaminoglycan (GAG) that was found to have multiple therapeutic effects in burns. Parenteral and topical application studies on GAGs revealed anticoagulative, anti-inflammatory and neoangiogenic properties [6]. The benefits of heparin in ILI have been shown in multiple studies. From burn animal models and human autopsies, ILI is generally believed to cause pathologic alteration which results in airway obstruction, pulmonary oedema, decreased pulmonary compliance and ventilation–perfusion mismatch [5], [7], [8], [9]. Administration of nebulised heparin combined with N-acetylcysteine (NAC) has shown to be able to reduce tracheobronchial cast formation and pulmonary oedema in smoke inhalation injury [6]. Desai et al. [10] have reported that heparin nebulisation in combination with NAC were able to decrease reintubation rates, incidence of atelectasis and mortality in paediatric burns patients. The combined efficacy of nebulised heparin, NAC and salbutamol in ILI was also demonstrated in a recent study conducted on adult burns patients with smoke inhalation injury and high acute physiology and chronic health evaluation (APACHE)-III scores [7]. In this group of patients, a reduction in lung injury scores was observed during the first week of treatment with the nebulised heparin, NAC and salbutamol protocol.

Nebulised heparin, NAC and salbutamol protocol was introduced in SGH Burns Centre in 2006. While the benefits of heparin have been illustrated in several studies, data on the safe use of nebulised heparin are limited [11], [12]. As with any therapeutic intervention, it is essential to weigh the benefits against the potential risks. Heparin, as an anticoagulant, is known to be capable of causing bleeding. However, the safety on the use of the nebulised form of heparin for burns patients with ILI is not well established. In this study, we investigated the safety and potential anticoagulant effects of nebulised heparin in burns patients with ILI.

Section snippets

Methodology

This study was a retrospective study with historical control. The study protocol was approved by the SingHealth Centralised Institutional Review Board.

Patient characteristics

63 patients and 104 patients were admitted to BICU from the year of 2001 to 2005 and 2006 to 2009, respectively. From the year of 2001 to 2009, a total of 167 patients were admitted to BICU (Fig. 1). Of which, 92 were not eligible for inclusion due to either absence of inhalational injury or they were not placed on mechanical ventilation. Eleven patients were excluded from the study as they were anticoagulated with enoxaparin upon admission and 1 patient was excluded as he was on warfarin prior

Discussion

The beneficial effects of heparin nebulisation in ILI, particularly when combined with mucolytics or antithrombin, were demonstrated in numerous studies [7], [10], [14], [15]. However, safety data on the use of nebulised heparin in the burns patient cohort is inadequate [11], [12]. As the airways and alveoli are capable of absorbing drugs delivered through the inhalation route and that heparin is able to increase the risk of bleeding, there may be a risk of systemic complications with the use

Conclusion

Findings from this study did not suggest any clinically significant increase in bleeding risk associated with nebulised heparin. When the therapeutic range of antithrombotic therapy was used as a gauge in the absence of established guideline available for nebulised heparin in burn patients with ILI, the coagulation indices were found to be in the clinically acceptable range. Our study suggested that nebulised heparin was not found to potentiate the risk of bleeding in burns patients with ILI.

Conflicts of interest

The authors declared that they have no potential conflicts of interest.

Acknowledgement

We would like to thank Ms. Stephanie Fook, biostatistician, for her advice on the statistical analysis of this study and the colleagues at Health Information Management System for tracing the casenotes of patients involved in this study.

Cited by (34)

  • Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment

    2022, Journal of Pharmaceutical Sciences
    Citation Excerpt :

    Another ongoing study weighs inhaled nanoparticle formulation of Remdesivir in terms of its safety, tolerability and pharmacokinetics on healthy subjects.107 Many clinical studies on the inhalation of Heparin and LMWH were conducted before the pandemic.108–120 According to van Haren et al., there is a strong scientific and biological basis to test the nebulized Heparin as a therapy for COVID-19 pneumonia and ARDS.

  • Erratum: Is inhaled prophylactic heparin useful for prevention and management of pneumonia in ventilated ICU patients? (Journal of Critical Care (2016) 35 (231–239)(10.1016/j.jcrc.2016.04.005)(S0883944116300296))

    2016, Journal of Critical Care
    Citation Excerpt :

    In asthma, larger doses of heparin have been used in bronchospasm provocation studies [54]. Although generally considered safe [38], a previous study documented that a persisting clinically significant coagulopathy was reported in relation to using doses of 5000 U of heparin nebulized every 4 hours which corrected on cessation of inhaled heparin therapy [37]. For this reason, patients receiving systemic anticoagulation were not enrolled in this trial to avoid the risks of excessive anticoagulation and the risks of bleeding.

  • Is inhaled prophylactic heparin useful for prevention and Management of Pneumonia in ventilated ICU patients?. The IPHIVAP investigators of the Australian and New Zealand Intensive Care Society Clinical Trials Group

    2016, Journal of Critical Care
    Citation Excerpt :

    It was unlikely that inhaled heparin would have a systemic effect on inflammatory processes or coagulation. Indeed, no differences were seen between the groups on coagulation tests or platelet counts consistent with other studies using similar doses of inhaled heparin [33–35]. The lack of any anti-inflammatory effect of inhaled heparin with severe pneumonia has been seen in animal models [36].

  • Inhalational use of antithrombotics in humans: Review of the literature

    2015, Thrombosis Research
    Citation Excerpt :

    This pilot study was not powered to detect any significant differences in lung function between the different doses of UFH received, but this was recommended by the authors. The safety outcomes of aerosolized heparin in the single case report of Yip, Lim and Chan [18] differ from those reported within the case series authored by Chopra, Burkey and Calaman [17]. Using similar doses of UFH in combination with N-acetylcystine in the setting of acute lung injury secondary to burns, Yip et al. reported significant coagulopathic complications associated with UFH administration, whilst Yip et al. reported no significant haematological impact.

  • Heparin derivatives for the targeting of multiple activities in the inflammatory response

    2015, Carbohydrate Polymers
    Citation Excerpt :

    It has been suggested that heparin may have the potential to relieve symptoms in lung conditions, ranging from the excess of NE in CF airways to asthma (Diamant et al., 1996) or even respiratory distress syndrome. Nevertheless, although several studies reported that heparin did not cause bleeding (Yip, Lim, & Chan, 2011) the effective dose of heparin (or low molecular weight heparin) required to achieve prolonged anti-inflammatory effects could result in anticoagulant complications. A solution to the problem of anticoagulant side-effects may be offered by chemically modified derivatives of heparin, which retain the desired activities, but exhibit attenuated anticoagulant activity (Lever & Page, 2002).

View all citing articles on Scopus
View full text